Donor human milk programs in German, Austrian and Swiss neonatal units - findings from an international survey

Daniel Klotz 1*, Stefanie Jansen 1, René Glanzmann 2, Nadja Haiden 3, Hans Fuchs 1 and Corinna Gebauer 4

Abstract
Background: Donor human milk (DHM) has been recommended for premature infants if mothers’ own milk is not available. The aim of this study was to increase the knowledge about the utilization rate and handling of DHM among neonatal units in Germany, Austria and Switzerland.

Methods: Online survey of utilization rates and handling practices of DHM of all neonatal units within Germany, Austria and Switzerland providing care for premature infants less than 32 weeks of gestation.

Results: DHM utilization rate of 35% is low (50/142) within those 54% of units that responded to our survey (142/261). Only 26/50 units have DHM routinely integrated into their nutritional management protocols. Lacking access and difficult procurement were cited as the main obstacles for not using DHM. However, eight out of ten respondents currently not using DHM would like to introduce DHM in their unit if available. There were differences in most aspects of DHM handling including donor recruitment and screening, testing and treatment of milk microbiota and commencement of DHM utilization. Breastmilk feeding rates were increased in units utilizing DHM compared to those not utilizing DHM.

Conclusions: DHM is underutilized in most neonatal units caring for premature infants within participating countries. Lacking access to DHM represents the main barrier for utilizing DHM for premature infants.

Keywords: Breast milk feeding, Donor, Human milk, Milk bank, Neonate, Preterm, Screening

Background
Donor human milk (DHM) is recommended for feeding premature infants when mothers’ own milk is unavailable or not fit for consumption [1, 2]. Donor human milk banks (DHMB) are the means by which DHM may be made available for premature infants. Subsequently, the number of DHMB is increasing in many parts of the world. Several national human milk bank associations described their DHMB networks and detailed their respective mode of operations [3, 4]. However, the knowledge about the actual DHM utilization rates in neonatal intensive care units providing care for very premature infants is limited [5–7]. The aim of this study is to provide an overview about the actual utilization rate of DHM, the procurement and handling of DHM, the implementation of feeding strategies using DHM or to identify the barriers to its use within German, Swiss and Austrian neonatal units. DHM programs and DHMB within these countries are established, operated and funded exclusively by individual neonatal departments setting their own policies concerning procurement and handling of human donor milk.

* Correspondence: daniel.klotz@uniklinik-freiburg.de
1 Center for Pediatrics and Adolescent Medicine, Department of Neonatology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
These data are needed to inform health care professionals, authorities and stakeholders about the extent and practice of current DHM programs within the participating countries, to support them to establish or evaluate local or national guidelines concerning DHM utilization and DHM handling and to improve the availability of DHM for preterm infants [8–10].

Methods
We sent a stratified online questionnaire to neonatologists within every neonatal unit that was providing care to preterm infants of less than 32 weeks of gestational age in Germany, Austria and the German speaking part of Switzerland.

The questionnaire was developed by the authors who are experienced in managing DHMB within their own neonatal departments and contained a maximum of 21 questions, depending on the strata. The questionnaire was pre-tested amongst neonatologists experienced with managing DHM programs. Participants were identified by personal knowledge or by internet research and consisted of individual neonatologists either in charge of the respective neonatal unit (i.e. the head of the neonatal department) or in charge of the DHM program of a respective neonatal unit. They were provided with information about the purpose of this study, the process of data collection and the intended publication of anonymized data. By replying to our survey, the contacted individuals consented to participate in this study. Withdrawal of their consent or supplied data and thus of participation, was possible at any time.

We asked participants to provide unit specific policies concerning the use of DHM, handling routines, the source of DHM and the overall breastfeeding rates at discharge for each unit. Screening of donors and donated milk, exclusion and reimbursement of donors were also surveyed. We inquired about the participant’s personal reasons to support the use of DHM in their unit. Rates of any or exclusive breast milk feeding (BMF) at discharge were sought. Barriers to prevent the use of DHM were enquired from those participants not utilizing DHM in their unit.

Data were collected from June 2016 to December 2018. The ethics committee of the Albert-Ludwigs-University, Freiburg, Germany, approved this study (No. 484/16).

We performed a descriptive analysis reporting quantitative data as mean and standard deviation or median and interquartile range where applicable. Categorical variables are presented in absolute numbers and percentages. The denominator represents the number of replies of any given questions to account for skipped questions. We applied a Wilcoxon rank sum test to compare unit size and breastfeeding rate between units and considered a p-value < 0.05 to be significant (GraphPad Prism V8, GraphPad, San Diego, CA).

Results
We contacted neonatologists from 261 different units and 142 of those replied (54%). One hundred and three of the participating units provided the highest level of neonatal care (level III) and 39 units provided level II neonatal care (Table 1).

The median (IQR) number of very low birth weight infants (VLBW) per unit with a birth weight < 1500 g was 52 (36–72) in the year prior to the survey participation.

Utilization of donor human milk
Any DHM was utilized in 50/142 neonatal units (35%). Within the year of participation, the median (range) number of neonates receiving any DHM per unit was 20 (2–59). Those units were caring for a median (IQR) of 61 (50–87) VLBW in the year prior to the survey participation, which compared to a median of 50 (33–67) VLBW in those 92 units that were not utilizing any DHM (p = 0.001).

DHM feeding was commenced either immediately after birth (n = 29), when mothers’ own milk was not available after a few days of life (n = 3), or commencement of feeding with DHM was decided on an individual basis (n = 13).

DHM was acquired from different sources. Most neonatal units with DHM programs operated an institutional DHMB (n = 27). In the remainder DHM was provided as a direct milk donation from another mother on the neonatal ward (n = 10) whereby the DHM was handled on the neonatal ward lacking the infrastructure and service of a dedicated DHMB. In some cases neonatal units without an own DHMB and that were not performing direct milk donations within their unit (n = 11) purchased DHM from other neonatal units, all of which operated a DHMB (n = 7). None of the neonatal units purchased commercially available DHM products within their year of survey participation.

No neonatal unit (and their respective DHMB) distributed DHM to private non-hospitalized individuals.

The main reasons to prefer DHM over preterm formula was improved neonatal short term outcome parameters (Fig. 1). Explicit parental request was cited by two participants as additional reason to feed DHM.

Non-availability of DHM and the complex process of procuring DHM were the main reasons for not utilizing DHM but general concerns about the use of DHM were also voiced (Fig. 2). However, eight out of ten respondents that did not have access to DHM would like to introduce DHM in their unit once it would become available, citing reasons similar to those participants already utilizing DHM.
Donor recruitment and donor screening
In 24 units donors are recruited amongst lactating mothers from other infants within the neonatal unit itself or the respective children’s hospital (e.g. mothers of infants suffering from congenital heart disease), recruited amongst lactating mothers from the community not being connected to the respective hospital (external milk donation, \(n=21\)) or recruited from both donor pools \((n=15)\).

A combination of a health history questionnaire regarding lifestyle, health indicators, medical and travel history, and serological testing to screen for donor eligibility was applied by all neonatal units that were procuring DHM (Table 2).

Additionally, according to individual participants’ comments, donors were questioned for any treatment with blood products or immunizations with live vaccines, international travel to certain geographic areas, new skin tattoos, permanent make up or piercings up to 6 months prior to DHM donation but these items were not systematically surveyed by our questionnaire. Donors to some neonatal units were tested for nicotine \((n=3)\), recreational drugs \((n=5)\), medication levels \((n=5)\) or alcohol levels \((n=2)\).

Actual donor expenses related to the donation, such as travel costs, were reimbursed by 12 units. In no instances were donors paid for sharing their milk.

Screening and handling of donor human milk
Donor milk was screened for bacterial count by 31/40 units. Screening was performed daily for every single bottle or pooled samples of DHM \((n=12)\), once a week \((n=10)\) or as random samples \((n=9)\). However, according to our survey DHM was not tested for bacterial contamination in nine cases. Post-pasteurization cultures of DHM and cytomegalovirus studies from DHM were rarely performed \((n=4)\). DHM was never tested for milk adulteration, e.g. adding water or non-human milk to

---

Table 1 Use of Donor human milk in participating neonatal units within Germany, Austria and Switzerland

| Level of neonatal care \(b\) | Germany | Austria | Switzerland \(a\) |
|-----------------------------|---------|---------|-----------------|
| Contacted centers \((n)\)   |         |         |                 |
| \(n\) %                     |         |         |                 |
| Response rate               |         |         |                 |
| \(n\) %                     |         |         |                 |
| Use of DHM                  |         |         |                 |
| \(n\) %                     |         |         |                 |
| Routinely                   |         |         |                 |
| \(n\) %                     |         |         |                 |
| Regularly                   |         |         |                 |
| \(n\) %                     |         |         |                 |
| Occasionally                |         |         |                 |
| \(n\) %                     |         |         |                 |
| Rarely                      |         |         |                 |
| \(n\) %                     |         |         |                 |

\(a\) German speaking part of Switzerland
\(b\) Level III = level of maximum care
\(c\) as part of a standardized feeding regimen
DHM donor human milk

---

Fig. 1 Reasons for using donor human milk amongst participants (multiple replies possible)
DHM or for toxicological substances, e.g. alcohol or recreational drugs.

Depending on the bacterial content, DHM was left untreated (i.e. unpasteurized after being refrigerated and frozen) in 7/41 units, Holder pasteurized (i.e. DHM heated at 62.5 °C for 30 min) in 25/41 units, subjected to short-time pasteurization (i.e. 62 °C for 5 s, \( n = 2 \)) or subjected to freeze-thawing (\( n = 11 \)) before being distributed to preterm infants. Only one unit used DHM that has never been frozen and remained unpasteurized after cultural testing for bacterial count and bacterial identification.

**Lactation consultation and breast milk feeding**

Lactations consultants were available in all but one unit. Rates of any BMF and for exclusive BMF at discharge from neonatal care were estimated by the participants for their respective unit. Rates of any BMF for preterm infants < 1500 g birthweight at discharge were increased in those units utilizing DHM (\( n = 45 \)) compared to those units (\( n = 91 \)) that are not utilizing DHM (median any BMF rate 71–80% versus 61–70%, \( p = 0.0008 \)). Estimated rates for exclusive BMF at discharge were also increased in those units supplying DHM compared to those not utilizing DHM (median exclusive BMF rate 51–60% versus 41–50%, \( p = 0.019 \)).

**Discussion**

Sixty-five percent of those neonatal units that were participating in our survey did not utilize DHM in their nutritional management of very premature infants. Only half of the units that were feeding DHM used it as part of routine nutritional management, and in a third of units, DHM appeared to be used on a case by case basis only. Neither the overall utilization rate nor the implementation in those units feeding DHM reflects the actual recommendations concerning the use of DHM for premature infants [1, 2]. This is in line with previous reports from other health care systems and underlines the need to improve the utilization rate of DHM and its implementation in clinical care [6, 7, 11].

Interestingly, some of the respondents that performed direct milk donations within their own unit did not consider themselves as maintaining a DHM program. However, the need for obtaining informed consent from
donors and parents of recipients, screening of donors and donated milk, preparation, distribution and tracking of DHM applies irrespective of the source of DHM. Therefore, any distribution of DHM within a health care facility may be considered as “milk banking” and should be subjected to adequate rigorous quality management according to the respective recommendations or regulations [12–14].

DHM screening for adulteration or substance abuse was not applied by our participants, this emphasizes the importance of donor screening and selection, especially when external milk donations are accepted. There was no reimbursement for milk donations to the non-profit DHM programs provided by neonatal departments in our cohort, this may reduce the financial incentive for milk adulteration that has been reported from commercially oriented milk sharing models [15].

Pasteurization of DHM is recommended to prevent the transmission of potentially harmful microbiota to the premature recipients [12, 16, 17]. The adverse impact of Holder-pasteurization on the quality of banked DHM is well known but alternatives to Holder pasteurization are limited [18, 19]. Freeze-thawing and short time pasteurization as performed in some units may not effectively inactivate cytomegalovirus or sufficiently reduce bacterial counts [20, 21]. Some units are dispensing unpasteurized DHM based on maternal cytomegalovirus (CMV) serostatus and on DHM bacterial counts for which many different threshold levels have been described and therefore remain somewhat arbitrary [22, 23].

Lactation and breastfeeding support are the prerequisites for any DHM program. All efforts must have been undertaken to provide mothers own milk first before considering an infant as a suitable DHM recipient. All but one unit offered such lactation support. However, we did not enquire about the level of expertise of these lactation consultants. Furthermore, lactation support should be available at all times but the number of lactations consultants needed to staff an effective lactation program remains to be determined [1, 24].

Estimated exclusive and any breastmilk feeding (BMF) rates at discharge did not indicate lower BMF rates in participating units utilizing DHM compared to those not utilizing DHM. We acknowledge the limited methodology, i.e. estimation, for assessing BMF rates. Our results however, are in line with previously published results that did not show decreased BMF rates in neonatal units offering DHM service [25, 26]. Nevertheless, the introduction of DHM may be detrimental to BMF efforts if mothers own milk is not adequately prioritized [27].

Lacking access to DHM was the main obstacle to utilize DHM and most participants would introduce DHM in their unit if accessible. Objections against the use of DHM were also raised by some respondents. These objections were not specified by our survey but should be addressed to understand the care providers’ concern and to identify further barriers for the use of DHM.

Some respondents purchased DHM from other neonatal departments. This may increase short-term availability and utilization of DHM but questions of inter-departmental DHM sharing (liability, regulatory framework and sustainability) remain. Costs of processing DHM are reported to exceed comparable costs for feeding mother’s own milk and preterm formula considerably [28]. Although cost effectiveness of DHM has been repeated demonstrated in other health care settings reimbursement for the procurement of DHM has not been established within the participating countries which may further limit the neonatal departments’ access to DHM [29].

Limitations
DHM utilization rate and handling procedures for DHM might have changed within the data acquisition period of this survey. However, this does not change our main finding of underutilization of DHM and our data may still provide a guiding framework for establishing DHM programs if national guidelines are not available. At the time of our survey the recently published guidelines of the European Milk Bank association were not available [12]. Therefore it would be worthwhile to review the variability of DHM handling practice and utilization over time. We aimed to distribute a concise and time efficient questionnaire. Therefore, we were not able to survey all different variations of DHM handling routines or to assess the percentage of eligible infants receiving DHM within a given unit. This may need a more in-depth analysis focusing on neonatal units DHM policies by other methods.

We surveyed the German speaking part of Switzerland only, therefore the degree to which these results can be generalized to the whole country is limited and due to a limited participation rate we might have underestimated the true extent of DHM utilization. Nevertheless, 27 of 33 neonatal units with officially listed DHMB within the three countries (as of December 2018) participated in this survey. Therefore, we included most of those units regularly handling and utilizing DHM.

Conclusions
Most participants would like to utilize DHM but lack access to DHM resulting in an underutilization of DHM within most German, Austrian and Swiss neonatal units compared to the existing recommendations. These
findings highlight the need to increase accessibility to DHM for premature infants [8].

Abbreviations
BMF: Breast Milk Feeding; CMV: Cytomegalovirus; DHM: Donor Human Milk; DHM®: Donor Human Milk Bank

Acknowledgments
The authors are indebted to all participants of this survey and to Gillian Weaver for further advice.

Authors’ contributions
DK, CG and HF conceptualized the study and designed the questionnaire. SJ and DK collected data and performed the data analysis. CG, RG, NH and HF contributed to data collection and analysis. All authors were involved in drafting, reviewing and contributing to the manuscript and approved the final version for submission.

Funding
The article processing charge was funded by the German Research Foundation (DFG) and the University of Freiburg in the funding programme Open Access Publishing. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
The ethics committee of the Albert-Ludwigs-University, Freiburg, Germany, approved this study (No. 484/16). By providing answers to this survey the respondents consented to participate.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
1. Center for Pediatrics and Adolescent Medicine, Department of Neonatology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 2. Department of Neonatology, University Children’s Hospital, Basel, Switzerland. 3. Department of Pediatrics and Adolescent Medicine, Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Medical University of Vienna, Vienna, Austria. 4. Department of Women’s and Children’s Health, Division of Neonatology, University Children’s Hospital, Leipzig, Germany.

Received: 19 December 2019 Accepted: 11 May 2020 Published online: 19 May 2020

References
1. Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 2012;129:e827–41.
2. ESPGHAN Committee on Nutrition, Arslanoglu S, Corpeleijn W, Moro G, Bogaer C, Campoy C, et al. Donor human milk for preterm infants: current evidence and research directions. J Pediatr Gastroenterol Nutr. 2013;57:355–42.
3. De Nisi G, Moro GE, Arslanoglu S, Ambruzzi AM, Biasini A, Profeti C, et al. Survey of Italian human milk banks. J Hum Lact. 2015;31:294–300.
4. Hagadorn JI, Brownell EA, Lussier MM, Parker MGK, Herson VC. Variability of Criteria for Pasteurized Donor Human Milk Use: A Survey of U.S. Neonatal ICU Medical Directors. JEN J Parenteral Enteral Nutr; 2014.
5. Berti E, Puglia M, Perugi S, Gagliardi L, Bosi C, Ingargiola A, et al. Feeding practices in very preterm and very low birth weight infants in an area where a network of human milk banks is in place. Front Pediatr. 2018;6.
6. Batterby C, Marciano Alves Mousinho R, Longford N, Modi N, UK neonatal collaborative Necrotising (UKNC-NEC) study group. Use of pasteurised human donor milk across neonatal networks in England. Early Hum Dev. 2018;118:32–6.
7. Perrine CG, Scanlon KS. Prevalence of use of human milk in US advanced care neonatal units. Pediatrics. 2013;131:1066–71.
8. Israel-Ballard K, Cohen J, Mansen K, Parker M, Engmann C, Kelley M, et al. Call to action for equitable access to human milk for vulnerable infants. Lancet Glob Health. 2019;7:e1484–6.
9. Matthias H, Haiden N, Abou-Dakn M, Berns M, Eglin K, Flemmer A, et al. Empfehlungen zur Förderung von Frauenmilchbanken in Deutschland, Österreich und der Schweiz (D-A-CH-Raum). Monatsschr Kinderheilkd. 2018;166:721–9.
10. Joohun F, Bührer C, Kauth T. Kommerzielle Muttermilchverstärker aus humaner Milch: unzureichend belegter Nutzen und hohe Kosten. Monatsschr Kinderheilkd. 2019;166:145–8.
11. Parker MGK, Barrero-Castiller A, Convin BK, Kavanagh PL, Belfort MB, Wang CJ. Pasteurized human donor milk use among US level 3 neonatal intensive care units. J Hum Lact. 2013;29:381–9.
12. Weaver G, Bertino E, Gebauer C, Grovslis A, Mileusnic-Milenovic R, Arslanoglu S, et al. Recommendations for the establishment and operation of human milk banks in Europe: a consensus statement from the European Milk Bank Association (EMBA). Front Pediatr. 2019;7.
13. Frischkleht K, Wälchli C, Annen V, Fuher T, Gianoli P, Stocker M. Leitlinie zur Organisation und Arbeitsweise einer Frauen-Milchbank in der Schweiz. Paediatr. 2010;21:19–24.
14. Muttermilch - Leitlinie Humanmilchbanken und Informationen für Milchspenderinnen | Gesundheitsförderung | Gesundheit | Sozialministerium. https://www.sozialministerium.at/cms/site/attachments/4/2/6/CH4012/CM5149423264631/leitlinie_humanmilchbank.pdf. Accessed 12 Nov 2019.
15. Keim SA, Kulkarni MM, McMamara K, Geraghty SR, Billock RM, Ronau R, et al. Cow’s milk contamination of human milk purchased via the internet. Pediatrics. 2015;135:e1157–62.
16. The Human Milk Banking Association of North America (HMBANA). Guidelines for the Establishment and Operation of a Donor Human Milk Bank. 10th Edition Fort Worth, 2018.
17. Centre for Clinical Practice at NICE (UK). Donor Breast Milk Banks: The Operation of Donor Milk Bank Services. London: National Institute for Health and Clinical Excellence (UK), 2010. http://www.ncbi.nlm.nih.gov/books/NBK66642/. Accessed 16 Nov 2015.
18. Maschmann J, Müller L, Lazar K, Goetz R, Hamprech K. New short-term heat inactivation method of cytomegalovirus (CMV) in breast milk: impact on CMV inactivation, CMV antibodies and enzyme activities. Arch Dis Child Fetal Neonatal Ed. 2019;104:604–6. https://doi.org/10.1136/archdischild-2018-316117.
19. Moro GE, Billeaud C, Rachel B, Calvo J, Cavallarin L, Christen L, et al. Processing of donor human Milk update and recommendations from the European Milk Bank Association (EMBA). Front Pediatr. 2019;7.
20. Klotz D, Schreiner M, Falcone V, Jonas D, Kunze M, Weber A, et al. High-temperature short-time treatment of human milk for bacterial count reduction. Front Pediatr. 2018;6.
21. Maschmann J, Hamprech K, Weissbrich B, Dietz K, Jahn G, Speer CP. Freezethawing of breast milk does not prevent cytomegalovirus transmission to a preterm infant. Arch Dis Child Fetal Neonatal Ed. 2006;91:F288–90. https://doi.org/10.1136/adc.2004.050625.
22. Klotz D, Jansen S, Gebauer C, Fuchs H. Handling of breast Milk by neonatal units: large differences in current practices and beliefs. Front Pediatr. 2018;6.
23. Omarsdottir S, Casper C, Akerman A, Polberger S, Vanpeé M. Breastmilk handling routines for preterm infants in Sweden: a national cross-sectional study. Breastfeed Med. 2008;3:165–70.
24. United States Lactation Consultant Association. International board certificiation lactation consultant staffing recommendations for the inpatient setting. 2010. http://www.ilca.org/files/USLCA/Resources/Publications/IBCLC_Staffing_Recommendations_July_2010.pdf. Accessed 3 Dec 2019.
25. Kanterowska A, Wei JC, Cohen RS, Lawrence RA, Gould JB, Lee HC. Impact of donor Milk availability on breast Milk use and necrotizing Enterococcal rates. Pediatrics. 2016;137:e201530035.
26. Wilson E, Edstedt Bonamy A-K, Bonet M, Toome L, Rodrigues C, Howell EA. Risk of reprocessing of donor breast milk for preterm infant. Arch Dis Child Fetal Neonatal Ed. 2006;91:F288–90. https://doi.org/10.1136/archdischild-2018-316117.
27. Parker LA, Cacho N, Engelmann C, Benedict J, Wymer S, Michael W, et al. Consumption of Mother's own Milk by infants born extremely preterm following implementation of a donor human Milk program: a retrospective cohort study. J Pediatr. 2019;211:33–8.

28. Fengler J, Heckmann M, Lange A, Kramer A, Flessa S. Cost analysis showed that feeding preterm infants with donor human milk was significantly more expensive than mother’s milk or formula. Acta Paediatrica. https://doi.org/10.1111/apa.15087.

29. Trang S, Zupancic JAF, Unger S, Kiss A, Bando N, Wong S, et al. Cost-effectiveness of supplemental donor Milk versus formula for very low birth weight infants. Pediatrics. 2018;141. https://doi.org/10.1542/peds.2017-0737.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.